BPC-157 Unknown Long-Term Safety: What the Evidence Shows

What the human evidence consists of

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice [1]. How it works in people is unknown: FDA's July 2026 review said its molecular targets have not been identified, that its mechanisms 'remain poorly understood', and that dose-response relationships for the effects reported in animals were not established [1]. The reported protections — against colonic fistulas, liver lesions and gut lesions — come from rat studies, not human trials [1].

A 2026 systematic review searched to June 1, 2026 for human studies of BPC-157 in orthopaedic and regenerative use and found three studies, 30 patients in total, all of poor methodological quality, with overall certainty of evidence rated very low. The reviewers concluded BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [2].

• Knee pain: a retrospective chart review at one Florida clinic of 17 patients injected into the knee; 16 were reached by phone, and 11 of the 12 who received BPC-157 alone reported significant improvement. There was no control group, no validated outcome tool, and results were recalled by patients [6].
• Interstitial cystitis: 12 women aged 39 to 76 who had not responded to pentosan polysulfate received a total of 10 mg injected around the bladder wall in one procedure; 10 reported complete symptom resolution and 2 reported about 80%, all patient-rated, with no placebo arm [7].
• Intravenous safety: 2 adults received 10 mg on day 1 and 20 mg on day 2, with no measurable change in tested heart, liver, kidney, thyroid or glucose markers and no side effects reported — a sample far too small to establish safety [8].

The only controlled human trial FDA found randomized 53 people with ulcerative colitis to an 80 mg BPC-157 enema or placebo daily for two weeks. It was reported only in a conference abstract, with too little detail to judge effectiveness [1]. FDA also found no human studies of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [1]. FDA noted that websites sell BPC-157 as capsules, injections, oral sprays and nasal sprays, some labeled 'for research purposes only', and that none of these products is FDA-approved [1].

What is known about harm

FDA searched its adverse-event database through December 4, 2025 and found three reports, all for injectable BPC-157: injection-site redness and swelling lasting nine days in a patient who also used a compounded thymosin; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred after re-exposure to a BPC-157 plus TB-500 'research' product. FDA said it cannot tell whether BPC-157 caused any of them [1].

In the small human studies FDA reviewed, no serious adverse events were reported, but the studies were short, small and gave limited safety information; in the healthy-volunteer enema studies the most frequent events were headache and flatulence [1].

Animal studies found changes in clotting time, liver enzymes, glucose and triglycerides. In 28-day intramuscular studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and raised liver enzyme (ALT), glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1]. The two-person intravenous pilot measured liver markers and blood glucose with no measurable change, but was too small to establish safety [8].

FDA raised concerns about possible immune reactions: compounded BPC-157 'may pose risk for immunogenicity for certain routes of administration', and may have problems with peptide-related impurities and characterization of the active ingredient [9].

Does the angiogenesis question hold up?

Reviews of animal and tissue experiments describe BPC-157 as having 'strong angiogenic potential' and as interacting with the nitric-oxide system, alongside protection of the endothelium [10][11]. That is a description of animal and laboratory work, not of a measured effect in people.

Diet: what is actually supported

None of the human studies described on this page tested a diet or food alongside BPC-157. In a rat experiment, BPC-157 interacted with the effects of L-arginine, an amino acid also sold as a supplement, on stomach lining injury and blood pressure [3]. That is animal work and does not show what happens when people combine the two.

Regulatory status: no approved product

BPC-157 is not an FDA-approved drug. No approved product contains it, there is no US Pharmacopeia or National Formulary monograph, and FDA's July 2026 review found no approved product containing it in any country it searched [1]. There is no FDA-approved dose because there is no approved product [1].

Its compounding status has moved. FDA listed BPC-157 among bulk substances with potential significant safety risks from September 2023 until April 22, 2026, then moved it to a 'nominated but withdrawn' table after the nominators withdrew; removal was not a finding of safety [9]. On July 23, 2026, an FDA advisory committee voted in favor of adding BPC-157 to the pharmacy bulks list. The vote was advice only, and adding it requires formal rulemaking [12]. FDA staff had recommended against adding it [1].

On October 28, 2026 HHS filed notice of a draft enforcement-discretion policy covering BPC-157 and five other peptides, saying HHS 'does not intend to take enforcement action' against state-licensed pharmacies, federal facilities and licensed physicians that meet its conditions while FDA's list is developed through rulemaking [4]. The conditions include BPC-157 acetate only, in subcutaneous, intramuscular, oral or topical forms, a single active ingredient, a patient-specific prescription and reporting of serious adverse events to MedWatch [13]. The notice says the policy does not establish rights and is not binding, and it does not put BPC-157 on any list or approve it [4]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [14].

WADA names BPC-157 in class S0, non-approved substances, prohibited at all times in and out of competition, and it stays named in the 2027 List that takes effect January 1, 2027 [5][15].

Bottom line

No long-term human safety data exist for BPC-157. The human evidence is a handful of small, uncontrolled or abstract-only studies [1][2], FDA's adverse-event database holds three reports it says it cannot attribute to the peptide [1], and the animal signals come from 28-day studies [1].